Novel Treatments for Chronic Viral Infections

ContraVir seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections, with an initial focus on herpes zoster, or shingles, and hepatitis B.

 

Combination Therapies for Hepatitis B

ContraVir is developing potentially curative combination therapies for chronic hepatitis B based on novel antiviral compounds.

CMX157 CRV431 Opportunity

 

A Shingles Treatment with Best in Class Potential

Our lead candidate is Valnivudine™, a potent oral antiviral being developed for the treatment of herpes zoster, commonly known as shingles. Valnivudine™ is well-tolerated and has been shown to reduce PHN pain in Phase 2 trials.

ContraVir is developing a portfolio of novel compounds against hepatitis B, including TXL™ (formerly CMX157), a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor. ContraVir is also developing Valnivudine™ (formerly FV-100), now in Phase 3 trials, for the treatment of herpes zoster, or shingles, and the pain associated with shingles.

Quick Links

ContraVir is focused on curing hepatitis B through combination of best-in-class, direct- and indirect-acting antiviral compounds. Its two current assets have complementary mechanisms of action against hepatitis B virus (HBV): TXL™ is a highly potent prodrug of tenofovir, marketed by Gilead as Viread®; CRV431 is positioned to be the leading next-generation cyclophilin inhibitor antiviral designed to selectively inhibit HBV.

TXL™ Highlights

  • Potential for lower dosing: 97-fold more potent than tenofovir in vitro
  • Potential to improve safety (reduced plasma exposure to tenofovir) compared to Viread®
  • Potential to improve efficacy (increased active tenofovir in target liver cells) compared to Viread®

CRV431 Highlights

  • Best-in-class potency and optimized selective index for HBV
  • Interrupts HBV life cycle at multiple points
  • Reduces liver injury through unique anti-fibrotic mechanism

ContraVir is developing Valnivudine™ as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles, an infection caused by the reactivation of the varicella zoster (chicken pox) virus. In addition to its potent antiviral activity, Valnivudine™ has demonstrated an ability to reduce shingles-associated pain, known as post-herpetic neuralgia, or PHN.

Valnivudine™ Highlights

  • Conducting a Phase 3 clinical study
  • Well-tolerated with demonstrated reduction in PHN in Phase 2 trials
  • Potential for more convenient dosing; no dose adjustment required for patients with renal insufficiency
  • Strong IP position